NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Celgene Corporation (NASDAQ: CELG) securities between September 12, 2016 and February 27, 2018 (the “Class Period”). Investors have until May 29, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On February 27, 2018, Celgene disclosed that it had received a refusal to file letter from the FDA in connection with the Company’s NDA for Ozanimod. The Company revealed that both the clinical and nonclinical pharmacology sections of its NDA were found deficient by regulators. On this news, the price of Celgene stock dropped 9%, or $8.66 per share, to close at $87.12 per share on February 28, 2018.
If you purchased or otherwise acquired Celgene securities and suffered a loss, continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Celgene Corporation lawsuit, please go to http://www.bespc.com/celgene. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.